- Home
- AUUD vs CERO Comparison
AUUD vs CERO Comparison
Compare AUUD & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUUD
- CERO
- Stock Information
- Founded
- AUUD 2012
- CERO 2017
- Country
- AUUD United States
- CERO United States
- Employees
- AUUD N/A
- CERO 8
- Industry
- AUUD Computer Software: Prepackaged Software
- CERO
- Sector
- AUUD Technology
- CERO
- Exchange
- AUUD Nasdaq
- CERO Nasdaq
- Market Cap
- AUUD 2.9M
- CERO 3.7M
- IPO Year
- AUUD 2021
- CERO N/A
- Fundamental
- Price
- AUUD $5.08
- CERO $0.45
- Analyst Decision
- AUUD
- CERO Buy
- Analyst Count
- AUUD 0
- CERO 2
- Target Price
- AUUD N/A
- CERO $3.00
- AVG Volume (30 Days)
- AUUD 57.8K
- CERO 993.4K
- Earning Date
- AUUD 06-17-2025
- CERO 05-15-2025
- Dividend Yield
- AUUD N/A
- CERO N/A
- EPS Growth
- AUUD N/A
- CERO N/A
- EPS
- AUUD N/A
- CERO N/A
- Revenue
- AUUD N/A
- CERO N/A
- Revenue This Year
- AUUD N/A
- CERO N/A
- Revenue Next Year
- AUUD N/A
- CERO N/A
- P/E Ratio
- AUUD N/A
- CERO N/A
- Revenue Growth
- AUUD N/A
- CERO N/A
- 52 Week Low
- AUUD $2.88
- CERO $0.40
- 52 Week High
- AUUD $31.62
- CERO $102.00
- Technical
- Relative Strength Index (RSI)
- AUUD 66.21
- CERO 35.19
- Support Level
- AUUD $4.43
- CERO $0.42
- Resistance Level
- AUUD $4.89
- CERO $0.50
- Average True Range (ATR)
- AUUD 0.38
- CERO 0.05
- MACD
- AUUD 0.10
- CERO 0.00
- Stochastic Oscillator
- AUUD 100.00
- CERO 24.77
About AUUD Auddia Inc.
Auddia Inc is a technology company that is engaged in radio broadcasts and streaming audio content digitally. Its products includes Auddia App which is a subscription-based commercial-free AM/FM software application, and Vodacast an interactive podcasting platform and application. The company generates revenue through subscription fees from customers accessing the company's cloud-based computing services and advertisement services.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.